Electrochemical LAMP-based assay for detection of RNA biomarkers in prostate cancer

Talanta. 2022 Feb 1;238(Pt 2):123064. doi: 10.1016/j.talanta.2021.123064. Epub 2021 Nov 13.


Current molecular diagnostics of prostate cancer relies on detection of elevated levels of PSA protein in serum, but its specificity has been questioned due to its higher levels also in non-malignant prostate diseases. A long non-coding RNA biomarker, PCA3, demonstrated excellent specificity for prostate cancer, and thus has become an interesting alternative to PSA monitoring. Its detection utilizes mostly reverse transcription PCR with optical detection, making the protocol longer and more expensive. To avoid PCR, we have developed an electrochemical assay coupled with LAMP, an isothermal amplification technique showing high sensitivities at constant temperatures and shorter reaction times. We amplified PCA3 RNA as well as PSA mRNA (serving as a control), hybridized LAMP products on magnetic beads and measured them with chronoamperometry at carbon electrode chips. We show good sensitivity and specificity for both biomarkers in prostate cancer cell lines, and successful detection of PCA3 in clinical samples, i.e., urine samples from 11 prostate cancer patients and 7 healthy controls, where we obtained excellent correlation with clinical data. This is to our knowledge a first such attempt to apply electrochemistry to determine two RNA biomarkers directly in urine samples of prostate cancer patients in a minimally invasive diagnostics format.

Keywords: Electrochemistry; Long non-coding RNA; PCA3; PSA; Prostate cancer; RNA biomarker.

MeSH terms

  • Antigens, Neoplasm* / genetics
  • Biomarkers
  • Biomarkers, Tumor / genetics
  • Humans
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / diagnosis
  • Prostatic Neoplasms* / genetics
  • RNA
  • Sensitivity and Specificity


  • Antigens, Neoplasm
  • Biomarkers
  • Biomarkers, Tumor
  • RNA
  • Prostate-Specific Antigen